Skip to main navigation
Skip to content

Infinity Pharmaceuticals, Inc

Search
  • Toggle search form
  • Follow us on Twitter
  • Connect with us on LinkedIn

Investor Relations

  • Our Team
    • Mission Values
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board
  • Our Development Program
    • Our Pipeline
    • Eganelisib
    • PI3K-Gamma
    • Selected Publications
    • Expanded Access
    • For Patients
  • For Patients
  • Investors/Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Leadership
      • Board of Directors
      • Committees
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Analyst Coverage
    • Online Investor Kit
    • Information Request
  • Join Us
    • Our Community
    • Life at Infinity
    • Careers
    • Benefits
  • Contact Us

Quarterly Results

Financial Information

  • Financial Information
  • SEC Filings
  • Annual Reports
  • Quarterly Results

2022

Q3

  • Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
  • Q3 2022 Infinity Pharmaceuticals, Inc. Earnings Conference Call
  • Form 10-Q

Q2

  • Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
  • Q2 2022 Infinity Pharmaceuticals, Inc. Earnings Conference Call
  • Form 10-Q

Q1

  • Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
  • Form 10-Q

2021

Q4

  • Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights
  • Form 10-K

Q3

  • Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
  • Form 10-Q

Q2

  • Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update
  • Form 10-Q

Q1

  • Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update
  • Form 10-Q

2020

Q4

  • Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development
  • Form 10-K

Q3

  • Infinity Pharmaceuticals Provides Company Update and Third Quarter 2020 Financial Results
  • Form 10-Q

Q2

  • Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results
  • Form 10-Q

Q1

  • Infinity Pharmaceuticals Provides Company Update and First Quarter 2020 Financial Results
  • Form 10-Q

2019

Q4

  • Infinity Pharmaceuticals Reports Full Year 2019 Financial Results and Provides Company Update
  • Form 10-K

Q3

  • Infinity Pharmaceuticals Provides Company Update and Third Quarter 2019 Financial Results
  • Form 10-Q

Q2

  • Infinity Pharmaceuticals Provides Company Update and Second Quarter 2019 Financial Results
  • Form 10-Q

Q1

  • Infinity Pharmaceuticals Provides Company Update and First Quarter 2019 Financial Results
  • Form 10-Q

2018

Q4

  • Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update
  • Form 10-K

Q3

  • Infinity Pharmaceuticals Provides Company Update and Third Quarter 2018 Financial Results
  • Form 10-Q

Q2

  • Infinity Pharmaceuticals Provides Company Update and Second Quarter 2018 Financial Results
  • Form 10-Q

Q1

  • Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results
  • Form 10-Q

2017

Q4

  • Infinity Pharmaceuticals Provides Company Update and Reports Fourth Quarter and Full Year 2017 Financial Results
  • Form 10-K

Q3

  • Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results
  • Form 10-Q

Q2

  • Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results
  • Form 10-Q

Q1

  • Infinity Provides Company Update and Reports First Quarter 2017 Financial Results
  • Form 10-Q

2016

Q4

  • Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results
  • Form 10-K

Q3

  • Infinity Provides Company Update and Reports Third Quarter 2016 Financial Results
  • Form 10-Q

Q2

  • Infinity Provides Company Update And Reports Second Quarter 2016 Financial Results
  • Form 10-Q

Shareholder Tools

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Print

    Print

  • Email

    Email

Infinity Pharmaceuticals, Inc.

1100 Massachusetts Ave
Cambridge, MA 02138
617-453-1000

Terms and Conditions

  • Terms & Conditions
  • Privacy Policy
  • Forward Looking Statements
Connect With Us
  • Twitter
  • LinkedIn

Our Team

  • Our Team
    • Mission Values
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board

Our Development Program

  • Our Development Program
    • Our Pipeline
    • Eganelisib
    • PI3K-Gamma
    • Selected Publications
    • Expanded Access
    • For Patients

Investor / Media

  • Investors/Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Online Investor Kit
    • Information Request

Join Us

  • Join Us
    • Our Community
    • Life at Infinity
    • Careers
    • Benefits
© 2023 Infinity Pharmaceuticals, Inc. All Rights Reserved.